Niclosamide potentiates TMEM16A and induces vasoconstriction

• Authors: Pengfei Liang, Duke University; Yui Chun S. Wan, Duke University; Kuai Yu, Emory University; H. Criss Hartzell, Emory University; Huanghe Yang, Duke University
• Journal Title: bioRxiv
• Publisher: NIH | 2023-08-02
• Type of Work: Article | Preprint: Prior to Peer Review
• Publisher DOI: http://doi.org/10.1101/2023.07.31.551400
• Subjects: Biology, Cell; Biology, Molecular
• Keywords: TMEM16A; ANO1; CaCC; Niclosamide; Blood vessel

Abstract

The TMEM16A calcium-activated chloride channel is a promising therapeutic target for various diseases. Niclosamide, an anthelmintic medication, has been considered as a TMEM16A inhibitor for treating asthma and chronic obstructive pulmonary disease, but was recently found to possess broad-spectrum off-target effects. Here we show that, under physiological conditions, niclosamide acutely potentiates TMEM16A without having any inhibitory effect. Our computational and functional characterizations pinpoint a putative niclosamide binding site on the extracellular side of TMEM16A. Mutations in this site attenuate the potentiation. Moreover, niclosamide potentiates endogenous TMEM16A in vascular smooth muscle cells, triggers intracellular calcium increase, and constricts the murine mesenteric artery. Our findings advise caution when considering niclosamide as a TMEM16A inhibitor to treat diseases such as asthma, COPD, and hypertension. The identification of the putative niclosamide binding site provides insights into the mechanism of TMEM16A pharmacological modulation, shining light on developing specific TMEM16A modulators to treat human diseases.